COMP <GO>
OVID vs AQST // RETURN ON INVESTED CAPITAL (ROIC)
Ovid Therapeutics Inc. (NASDAQ) VS. Aquestive Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OVID 6
— AQST 0
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: OVID
LAST: $2.39 (-5.91%) • MKT CAP: $496.1M
roic
-28.50%
LAST: $3.77 (-3.08%) • MKT CAP: $488.2M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OVID VS. AQST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OVID | AQST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 58.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -28.50% | -35.00% | +6.50 | OVID | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.67% | -10.45% | +2.78 | OVID | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | -22.60% | +202.60 | OVID | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.46 | 0.20 | +11.26 | OVID | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.8 | 39.2 | +16.60 | OVID | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $496.1M | $488.2M | $7.8M | OVID | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OVID REV | AQST REV | OVID GROSS % | AQST GROSS % | OVID FCF | AQST FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.3M | $44.5M | — | 58.3% | -$38.3M | -$53.0M |
| FY 2024 | $566.0K | $57.6M | — | 69.0% | -$56.0M | -$35.9M |
| FY 2023 | $392.0K | $50.6M | — | — | -$45.8M | -$6.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OVID // BETA —
AQST // BETA —